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Nemaline myopathy (NM) is a rare congenital myopathy characterised by hypotonia, muscle weakness, and often
skeletal muscle deformities with the presence of nemaline bodies (rods) in the muscle biopsy. The nebulin (NEB) gene
is the most commonly mutated and is thought to account for approximately 50% of genetically diagnosed cases of
NM. We undertook a detailed muscle morphological analysis of 14 NEB-mutated NM patients with different clinical
forms to define muscle pathological patterns and correlate them with clinical course and genotype. Three groups were
identified according to clinical severity. Group 1 (n = 5) comprises severe/lethal NM and biopsy in the first days of life.
Group 2 (n = 4) includes intermediate NM and biopsy in infancy. Group 3 (n = 5) comprises typical/mild NM and biopsy
in childhood or early adult life. Biopsies underwent histoenzymological, immunohistochemical and ultrastructural
analysis. Fibre type distribution patterns, rod characteristics, distribution and localization were investigated. Contractile
performance was studied in muscle fibre preparations isolated from seven muscle biopsies from each of the three
groups. G1 showed significant myofibrillar dissociation and smallness with scattered globular rods in one third of fibres;
there was no type 1 predominance. G2 presented milder sarcomeric dissociation, dispersed or clustered nemaline
bodies, and type 1 predominance/uniformity. In contrast, G3 had well-delimited clusters of subsarcolemmal elongated
rods and type 1 uniformity without sarcomeric alterations. In accordance with the clinical and morphological data,
functional studies revealed markedly low forces in muscle bundles from G1 and a better contractile performance in
muscle bundles from biopsies of patients from G2, and G3.
In conclusion NEB-mutated NM patients present a wide spectrum of morphological features. It is difficult to establish
firm genotype phenotype correlation. Interestingly, there was a correlation between clinical severity on the one hand
and the degree of sarcomeric dissociation and contractility efficiency on the other. By contrast the percentage of fibres
occupied by rods, as well as the quantity and the sub sarcolemmal position of rods, appears to inversely correlate with
severity. Based on our observations, we propose myofibrillar dissociation and changes in contractility as an important
cause of muscle weakness in NEB-mutated NM patients.
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Nemaline myopathy (NM) is a congenital muscle disorder
associated with hypotonia, muscle weakness, and often
skeletal muscle deformities with the presence of numerous
nemaline bodies (rods) in muscle biopsy [1]. Clinically the
disorder has a marked clinical variability, ranging from
neonatal lethal to mild non-progressive forms with onset
in childhood and adulthood. NM has been classified
into six clinical categories according to the severity of
the disease, the age of onset and the pattern of
muscle weakness [2]. To date at least nine genes have
been implicated in NM (ACTA1, MIM#161800; NEB,
MIM#256030; TPM2, MIM#609285; TPM3, MIM#609284;
TNNT1, MIM#605355; KBTBD13, MIM#609273; CFL2,
MIM#610687; KLHL40 MIM#615340; and KLHL41)
encoding proteins of the thin filament of skeletal muscle
sarcomere or the Kelch domain associated proteins [3-11].
ACTA1, TPM2 and TPM3 NM is inherited both as auto-
somal dominant or recessive trait, with de novo dominant
mutations being common in all three genes. KBTBD13
NM is an autosomal dominant disorder. The other five
genes present autosomal recessive mode of inheritance.
Nebulin is a sarcomeric structural protein crucial for
the proper assembly and function of thin filaments [12].
One molecule spans nearly the entire length of the thin
filament, making nebulin one of the largest polypeptides in
nature. The nebulin (NEB) gene is the most commonly
mutated and is thought to account for approximately 50%
of genetically diagnosed cases of NM [12]. It is composed
by 183 exons of which at least 17 [13] have been shown to
be alternatively spliced, giving rise to several different
nebulin isoforms in skeletal muscle [14]. Molecular
diagnosis has mostly been based on dHPLC and confirmed
by exon Sanger sequencing which are time-consuming,
laborious, and expensive [15]. Recently next generation
sequencing technology in combination with microarray
methodology [16] has been demonstrated to be a fast and
reliable tool for analysis of large genes such as NEB [15].
Patients are usually compound heterozygous for two
different mutations [17]. The mechanisms leading to the
alteration of muscle structure or rod formation are largely
unknown.
Nemaline bodies are the pathologic hallmarks of
congenital NM, even if these structures may sometimes be
found associated with other conditions [18]. These are
protein aggregates staining red with the modified Gomori
trichrome technique. They can appear within the fibres as
fine isolated/diffuse structures, compact subsarcolemmal
clusters, or both [19]. On electron microscopy, nemaline
bodies are electron dense and generally measure 1–7 μm
in length and 0.3-2 μm in width. Due to their structural
continuity with the Z-disk, and their resemblance to
Z-disk lattice pattern, they are considered to be lateral
expansions of the Z-disk [20-22]. In the case of nebulinmutation the rod formation could be due to a defect of
the nebulin C-terminal, and serine-rich (SH3) domains.
Concordantly, the nebulin C-terminal region, or part of it,
may extend into the Z-disk [23]. Another common
histologic finding of NM is type 1 predominance or
type 1 uniformity [21,22]. Based on observations from
consecutive muscle biopsies done in the same patient,
a substitution of type 2 to type 1 fibres has been suggested
to occur with increasing age [19,24]. All congenital NM
patients seem to present a homogeneous morphological
phenotype characterised by the presence of rods and type
1 predominance. However the largest series reporting
on histologic NM findings were published before the
identification of specific NM genes or they included
patients harbouring mutations in other genes [22,25].
For this reason it is difficult to assess the existence of
specific genotype-morphological phenotype correlations in
the nine genetically identified forms of NM. A systematic
morphological analysis of each entity is therefore pivotal in
order to reveal pathogenetic mechanisms.
With the aim of characterising different patterns of
muscle involvement, defining the relationship between
morphological changes, genotype, and disease severity,
we describe muscle morphology and functional studies
of a large cohort of clinically heterogeneous NEB-mu-
tated NM patients.
Material and methods
Patients
Fourteen patients from 13 unrelated families from France,
the French Antilles, and Argentina were included in the
present study. Patients were classified into three groups
according to their clinical disease severity. P4 and P5 are
brothers. P1 to P5 (Group 1) presented a severe/lethal
congenital myopathy leading to death in the first days of
life. Their muscle biopsy was performed between 2 days
and 15 days of life. P6 to P9 presented an intermediate
congenital myopathy and a biopsy effectuated between 2
and 10 months (Group 2); P10 to P14 presented typical or
mild (P13, and P14) nemaline myopathy and a muscle
biopsy performed during childhood or adolescence/early
adult life (6 months-21 years; Group 3). The clinical
data of these patients were systematically retrieved
and retrospectively analysed. Patients were personally
examined by one of 6 of the authors. Clinical and
genetic characterization of P1, P2, P4, and P5 has been
previously reported [4,15,26].
Mutation analysis
Patients or parents gave informed consent for the genetic
analysis according to French legislation (Comité de
Protection des Personnes Est IV DC-2012-1693). Genomic
DNA was extracted from blood by standard methods. As
nemaline myopathy (NM) is genetically heterogeneous and
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impedes classical sequences approaches [12], we performed
exome sequencing on 5 μg of genomic DNA from the
patients and their parents as in Böhm et al. [15].
Exome sequencing was performed at the BGI (Shenzhen)
on a Hiseq 2000 (Illumina) by using the Agilent
44 M v2 SureSelect Exon enrichment kit. Variant calling
was done with the SOAP software. Variants filtering and
prioritization were performed by comparison with SNP
databases and with the VaRank program [27]. We
discarded polymorphisms with a minor allele frequency
(MAF) of more than 0.5% and excluded all variants with a
frequency <20% of the total reads for a specific position.
Additionally dHPLC and Sanger sequencing was per-
formed in 7 patients as reported in Lehtokari et al. [17].
The mutations are reported according to the coding
sequence of the nebulin cDNA reference sequence
NM_001164508.1, and its translation.
RT-PCR
RNA was extracted from muscle biopsies with TRI-Reagent
(Sigma), and cDNA was reverse transcribed using the
SuperScript II Reverse Transcriptase (Invitrogen) and
random hexamer primers. The PCR fragments of selected
cDNA regions were cloned into the pGEM-T easy vector
(Promega) and transformed into E. coli DH5alpha cells.
Plasmid DNA was then extracted from single colonies and
Sanger sequenced.
Morphological studies
An open muscle biopsy was performed in all patients
after informed consent. Age at biopsy varied from
29 weeks of adjusted gestational age to 21 years. The
biopsied muscle is reported in Table 1 and was deltoid
in 9 patients (P1, P2, P3, P5, P6, P9, P10, P13, and P14)
and vastus lateralis in 5 (P4, P7, P8, P11, and P12). In
order to make a precise and comparative study of
muscle biopsy findings in Group 1 we standardized the
age of new-borns calculating their ‘gestational adjusted
age’ as described in Shichiji et al. [28] (Table 1). Samples
were analysed in our research laboratory at the Myology
Institute in Paris or in the Neuropathology laboratory of
FLENI Institute and Garrahan Hospital in Buenos Aires,
Argentina. For conventional histochemical techniques
10 μm thick cryostat sections were stained with
haematoxylin and eosin (H&E), modified Gomori tri-
chrome (mGT), Periodic acid Schiff technique (PAS),
Oil red O, reduced nicotinamide adenine dinucleotide
dehydrogenase-tetrazolium reductase (NADH-TR), succinic
dehydrogenase (SDH), cytochrome c oxidase (COX), and
adenosine triphosphatase (ATPase) preincubated at pH 9.4,
4.63, 4.35. Digital photographs of each biopsy were
obtained with a Zeiss AxioCam HRc linked to a Zeiss
Axioplan Bright Field Microscope and processed withthe Axio Vision 4.4 software (Zeiss, Germany). The fibre
type pattern was determined by counting 1000 fibres from
each patient in ATPase 9.4 and 4.35 reactions, and by
calculating the percentage of type 1 and type 2 fibres.
Based on our experience, and the fibre type proportion
reported in the literature regarding the muscle analysed,
we considered type 1 fibres predominance to be present
when there were more than of 60% type 1 fibre in
deltoid muscles, and more than 40% in vastus lateralis
muscle [29]. Fibre type distribution in G1 patients was
analysed comparing the data on muscle fibre patterns
during the main phases of skeletal muscle development
obtained from individual with no neumuscular disorder
[30,31]. Moreover, where possible, we analysed fibre type
proportion in age-matched control biopsies corresponding
to G2, and G3 patients.
For the analysis of the proportion of fibres with rods,
800–1000 fibres of the muscle sections of each patient
were analysed, and the percentage of fibres appearing
with and without rods on the total number of fibres
of a muscle sections was calculated; four consecutive,
non-overlapping fields were counted. In addition, a
classification of the rods and their pattern was effectuated.
We defined the rods as being cytoplasmic when localised
mainly inside the fibres sparing the subsarcolemmal
areas, scattered when they were randomly distributed
in the muscle fibre, diffuse, when several small rods
were distributed across the whole fibres homogenously
occupying the majority of their area, central when distrib-
uted mainly in the centre of the cytoplasm, and subsarco-
lemmal when they were localized in a compact manner
close to the fibre membrane (as clusters). We also
evaluated the shape of nemaline bodies being mainly
globular/ovoid, squared, or elongated.
Immunohistochemistry and immunofluorescence
Frozen muscle samples for immunohistochemical and
immunofluorescence analyses were available for 7 patients
(P1, P6, P7, P9, P10, P11, and P14). Myosin heavy chain
fast (NCL-MHCf, Novocastra Laboratories, Newcastle
Upon Tyne, United Kingdom), myosin heavy chain slow
(NCL-MHCs, Novocastra Laboratories, Newcastle Upon
Tyne, United Kingdom), myosin heavy chain developmen-
tal (NCL-MHCd, Novocastra Laboratories, Newcastle
Upon Tyne, United Kingdom), myosin heavy chain neo-
natal (NCL-MHCn, Novocastra Laboratories, Newcastle
Upon Tyne, United Kingdom). Antibodies were visualized
using immunoperoxidase techniques [28]. Myosin alpha
and beta-slow heavy chain, fast 2A heavy chain, and
2X myosin heavy chain (BA-D5, SC-71, and 6H1,
Developmental Studies Hybridoma Bank, University
of Iowa, Iowa City, USA) immunofluorescence were
assessed on 10-μm-thick cryosections over night at 4°C.
Subsequently, sections were incubated with appropriate
Table 1 Clinical, laboratory, and genetic features of patients
Patient sex
current age
Ethnic origin
consanguinity
Age at onset
(Gestational age)
Biopsied
muscle
Age at
biopsy
Morphological
methods
(Functional
studies)
Clinical phenotype Permanent
mechanical
ventilation/age
NEB mutation:
nucleotide/protein
change
Effect of the
mutations
Reference
P1, F,
deceased
10 days
French
Caucasian,
Yes
Antenatal
(38 weeks)
Deltoid
2 days
IHC, IF,
EM (Yes)
Group 1/Severe congenital
nemaline myopathy
Polyhydramnios, fœtal
akinesia. Severe global
hypotonia, respiratory
distress, arthrogryposis,
hip hyperlaxity, club feet
and dysmorphic features.
Yes From
birth
ex45; c.5574C >G;
p.Tyr1858Stop; int122;
c.19101 + 5G>A;
p.Leu6333_Glu6367del
exon 45: nonsense
mRNA decay (by RTPCR)
exon 122: skipping
confirmed by RTPCR
and sequencing cDNA
Böhm et al.,
[15]
P2, F,
deceased
at 1 month
French Jewish
(Ashkenazi) Yes
Antenatal,
(36 weeks)
Deltoid
5 days
IHC, EM
(No)
Group 1/Severe congenital
nemaline myopathy
Polyhydramnios, fœtal
akinesia. Severe global
hypotonia, respiratory
distress, arthrogryposis,
club feet and dysmorphic
features.
Yes From
birth
homozygous
deletion
of exon 55
Ashkenazi founder
mutation; deletion
of exon 55
Lehtokari et al.,
[26]
c.7432 + 1916_7535 +
372del p.Arg2478_
Asp2512del
P3, M,
deceased
at 6 days
French
Caucasian,
No
Antenatal
(38 weeks)
Deltoid
6 days
IHC, EM
(No)
Group 1/Severe congenital
nemaline myopathy
Polyhydramnios, fœtal
akinesia. Severe global
hypotonia, respiratory
distress, arthrogryposis,
club feet, and dysmorphic
features.
Yes From
birth
ex86 (triplicated
region); c.13066delT;
p.Tyr4356Thrfs*8 ex110;
c.17535G > A;
p.Glu5845Glu
exon 86: frameshift
mutation leading
to either truncation
or degradation.
exon 110: splice
site mutation
Present paper
P4, M,
deceased
at 5 days,
Brother of P5
French
Caucasian,
Yes
Antenatal
(29 weeks)
Vastus
lateralis
3 days
IHC
(No)
Group 1/Severe congenital
nemaline myopathy
Polyhydramnios, fœtal
akinesia. Severe global
hypotonia, absence of
spontaneous movements
at birth, respiratory distress,
macrosomy and macrocephaly.
Yes From
birth
ex177; c.24686_
24687del; p.Glu8229
Glufs*18
both mutations
truncating/degrading
Pelin et al.,
[4]
Lehtokari et al.,
[17]
ex163; c.23420_
23421del; p.Arg7807
Serfs*16
P5, M,
deceased
at 29 days,
Brother of P4
French
Caucasian,
Yes
Antenatal
(36 weeks)
Deltoid
15 days
IHC, EM
(No)
Group 1/Severe congenital
nemaline myopathy
Polyhydramnios, macrosomy
Severe global hypotonia,
respiratory distress,
reduced spontaneous
movements, ptosis,
arthrogryposis, hypetrichosis,
and macrocephaly.
Yes From
birth
ex177; c.24686_
24687del; p.Glu8229
Glufs*18
both mutations
truncating/degrading
Pelin et al.,
[4]
Lehtokari et al.,
[17]
ex163; c.23420_
23421del; p.Arg7807
Serfs*16
P6, M,
deceased
at 5 months
French
Caucasian,
No
Birth
(39 weeks)
Deltoid
9 weeks
IHC, IF,
EM (No)
Group 2/Intermediate
congenital nemaline
myopathy Hypotonia
and poor spontaneous
Yes From
1 month
ex6; c.300dup;
p.Tyr101fs*5 int49,
c.6496-G > A,
p.2166_2234del
exon 6: truncating/
degrading exon 50
skiping by RT and
cDNA sequencing
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Table 1 Clinical, laboratory, and genetic features of patients (Continued)
movements at birth.
At one month
respiratory distress
and deglutition
problems. Elongated
face. High-arched
palate. Low-set ears.
Facial diplegia.
P7, F,
deceased at
2 and half yrs
African, Yes 11 days
(39 weeks)
Vastus
lateralis
6 months
IHC, IF,
EM (Yes)
Group 2/Intermediate
congenital nemaline myopathy.
Apparently normal at birth.
Successively hypotonia and
deglutition problems. At
1.5 months development of
progressive respiratory failure
followed by recuperated
cardiac arrest.
Yes From
2 months
homozygous 177;
c.24735-24736DelA_
fsx1 is this c.24735_
24736del (AG)
p.Arg8245fs*1
truncating/degrading Present paper
P8, M
5 yrs
Argentinian,
No
6 months
(40 weeks)
Vastus
lateralis
6 months
IHC,
EM (Yes)
Group 2/Intermediate
congenital nemaline
myopathy Hypotonia,
motor delay. High-arched
palate. Proximal and
distal muscle weakness.
Retractions of fingers.
Mild hyperlaxity. At
1 year development
of progressive respiratory
involvement necessitating
tracheostomy.
Yes From
1 month
ex139; c.20928G >
T; p.Gly6976Gly
RTPCR and Sanger
sequencing of cDNA
showed that instead
of 105 nt, exon 139
contains only 34 nt:
frameshift and a
premature stop
codon. Exon 172;
truncating/degrading
Present paper
ex172; c.24269del
p.Arg8090fs*54
P9, M,
11 yrs
French
Caucasian,
Yes
Birth
(39 weeks)
Deltoid
10 months
IHC, IF,
EM (Yes)
Group 2/Intermediate
congenital nemaline
myopathy Shortly
after birth severe
respiratory failure.
Tracheostomy and
gastrostomy at five
months. Facial diplegia,
drooling, deglutition
problems. Axial
hypotonia and
weakness of all limb
muscles.
Yes From
5 months
homozygous ex174;
c.24440_24441insGTCA,
p.Pro8148Serfs*15
truncating/degrading Present paper
P10, M,
17 yrs
French
Caucasian,
No
6 years
(At term)
Deltoid
6 years
IHC, IF,
EM (Yes)
Group 3/Typical
congenital nemaline
myopathy. Global
hypotonia, deglutition
problems. Proximal
muscle weakness.
Facial diplegia. Nasal
voice. Mild respiratory
No int43; c.5343 + 5G > A
p.Arg1747_Thr1778del
ex153; c.22273del
p.Val7425Serfs49*
intron 43: a splice
site mutation exon153:
truncating/degrading
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Table 1 Clinical, laboratory, and genetic features of patients (Continued)
insufficiency treated
with discontinuous
non-invasive ventilation.
P11, M,
19 years
French
Antillean
No
1 yrs
(At term)
Vastus
lateralis
6 yrs
IHC, IF,
EM (Yes)
Group 3/Typical congenital
nemaline myopathy.
Hypotonia and feeding
difficulties. Delayed
motor milestones. Facial
weakness with open
mouth. Axial and limb
girdle proximal weakness.
Mild respiratory involvement
treated with discontinuous
non-invasive ventilation.
No ex175; c.24579G > A,
p.Ser8193Ser ex119;
c.18676C > T, p.Gln6226*
ex175: a splice site
mutation ex119: a
nonsense mutation
(truncating/degrading)
Present paper
P12, M,
20 yrs
French
Caucasian,
No
2-3 years
(At term)
Vastus
lateralis
6 years
IHC,
EM (No)
Group 3/Typical congenital
nemaline myopathy.
Difficulties in running
and rising stairs. Facial
weakness with open
mouth. Mild upper
and lower limb girdle
weakness.
No int155; c.22591-3C >
G; p.7531Val_
Ser7564del; ex148;
c.21796_21810delinsT;
p.Pro7266fs*30
intron 155: a splice site
mutation exon 148:
truncating/degrading
Present paper
P13, F, 52 yrs French
Caucasian,
No
6 yrs
(At term)
Deltoid
18 years
IHC,
EM (No)
Group 3/Mild congenital
nemaline myopathy.
Difficulties in sport
activities in school.
Bilateral pes cavus.
Presence of mild
upper girdle musle
weakness. Diffuse
muscle pain.
No ex69; c.10043_
10046del,
p.Val3348Alafs
*43 ex49; c.6388G > C
p.Ala2130Pro
ex69: truncating/
degrading ex49:
missense on the
acting binding site
Present paper
P14, F, 37 yrs French
Caucasian,
No
2 yrs
(At term)
Deltoid
21 yrs
IHC, IF,
EM (Yes)
Group 3/Mild congenital
nemaline myopathy.
Frequent falls. Difficulties
in running , rising stairs.
Jaw contractures. Nasal
voice. Elongated face.
Respiratory involvement.
Axial weakness with
difficulties in neck flexion.
Asymmentrical distal
weaakness with foot
drop (right > left).
Proximo-distal weakness.
No int17; c.1569 + 1G >
A p.His491_Asp523del
intron 17: a splice
site mutation
Present paper
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Fluor-488 green goat anti-rabbit antibody, and Alexa
Fluor-594 red goat anti-mouse antibody, Molecular
Probes, Cergy Pontoise, France). A set of control slides
was prepared with omission of the primary antibodies.
Electron microscopy
Detailed electron microscopy analysis was prospectively
performed in thirteen patients. Small muscle specimens
were fixed with glutaraldehyde (2.5%, pH 7.4), post fixed
with osmium tetroxide (2%), dehydrated and embedded in
resin (EMBed-812, Electron Microscopy Sciences, USA).
Ultra-thin sections from at least three small blocks
from each patient were stained with uranyl acetate
and lead citrate. The grids were observed using a Philips
CM120 electron microscope (80 kV; Philips Electronics
NV, Eindhoven, The Netherlands) and were photo
documented using a Morada camera (Soft Imaging
System, France).
Muscle contractility experiments
To investigate whether the contractile performance is af-
fected in muscle biopsies from patients with mutations
in the nebulin gene, we performed skinned muscle fibre
contractility experiments. Small strips were dissected
from muscle biopsies of patients P1 (Group 1), P7, P8
and P9 (Group 2), and P10, P11 and P14 (Group 3) and
were skinned overnight as described previously [32]. The
skinning procedure renders the membranous structures
in the muscle fibres permeable, which enables activation
of the myofilaments with exogenous Ca2+. Preparations
were washed thoroughly with relaxing solution and
stored in 50% glycerol/relaxing solution at −20°C. Small
muscle preparations (cross-sectional area ~0.002 mm2)
were dissected from the skinned strips, and were mounted
using aluminum T-clips between a length motor (ASI
403A, Aurora Scientific Inc., Ontario, Canada) and a force
transducer element (ASI 315C-I, Aurora Scientific Inc.,
Ontario, Canada) in a single fibre apparatus (ASI 802D,
Aurora Scientific Inc., Ontario, Canada) that was mounted
on an inverted microscope (Zeiss Axio Observer A1).
Sarcomere length was set using a high speed VSL camera
and ASI 900B software (Aurora Scientific Inc., Ontario,
Canada). Mechanical experiments were performed at a
sarcomere length of ~2.2 μm, a length selected to minimize
force differences due to shorter thin filaments in fibres
from nemaline myopathy patients with nebulin mutations
[32]. Fibre width and diameter were measured at three
points along the fibre and the cross-sectional area was
determined assuming an elliptical cross-section. Two
different types of bathing solutions were used during the
experimental protocols: a relaxing solution (40 mM BES;
10 mM EGTA; 6.86 mM MgCl2; 5.96 mM Na-ATP;
3.28 mM K-propionate; 33 mM creatine phosphate; 1 mMDTT; 0.5 mM PMSF; 0.2 mM Leupeptin; 0.05 mM E64)
and an activating solution (40 mM BES; 10 mM
CaCO3-EGTA; 6.64 mM MgCl2; 6.23 mM Na-ATP;
2.1 mM K-propionate; 15 mM creatine phosphate; 1 mM
DTT; 0.5 mM PMSF; 0.2 mM Leupeptin; 0.05 mM E64).
The temperature of the bathing solutions was controlled by
a TEC controller (ASI 825A, Aurora Scientific Inc. Ontario,
Canada). Muscle preparations were mounted in a relaxation
solution at 1°C. Subsequently, the muscle preparations were
pre-activated by switching to an activation solution at 1°C.
In that way the myofibres are loaded with calcium, but no
force is generated. By rapid switching to an activation
solution at 20°C, the fibres were activated and force
was generated. When the force trace reached a plateau, the
muscle fibres were slacked to 70% of their original length
followed by a rapid restretch to the original length after 30
milliseconds. This procedure allows the force to redevelop
from zero [33]. The rate of tension redevelopment
was calculated by fitting a bi-exponentional through
the force redevelopment curve. The first-order rate
constant k1 reflects crossbridge cycling kinetics and was
therefore used in the analyses [34].Myosin heavy chain composition of bundles used for
contractility experiments
For determination of the myosin heavy chain isoform
composition of the muscle fibre preparations we used
specialized SDS-PAGE [32]. In brief, muscles fibres were
denatured by boiling for 2 minutes in SDS sample buffer.
The stacking gel contained a 4% acrylamide concentration
(pH 6.7), and the separating gel contained 7% acrylamide
(pH 8.7) with 30% glycerol (v/v). The gels were run for 24 h
at 15°C and a constant voltage of 275 V. Lastly, the gels
were silver-stained, scanned, and analysed with One-D scan
EX software (Scanalytics Inc., Rockville, MD, USA).
The ethical committee of La Pitié-Salpêtrière Hospital
(CCPPRB) approved this study.Results
Clinical findings
Five patients were female and 9 were male. Clinical sum-
mary, laboratory features, a complete list of morphological
methods, functional studies applied to muscle biopsies, and
genetic characterization of all patients is provided in Table 1.
Patient 6 and 7 were classified to be a part of intermediate
congenital nemaline myopathy group because they were
breathing and moving at birth. However, these patients
developed soon after birth a severe clinical picture and they
were never able to achieve respiratory independence and/or
ambulation. They eventually deceased at 5 months, and
32 months respectively. They therefore present a phenotype
in between a severe and an intermediate congenital
nemaline myopathy.
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To identify the genetic cause in this cohort of patients,
we performed exome enrichment and sequencing on
genomic DNA from the patients and their parents.
Exome sequencing allows a rapid and parallel screening
of most human genes, and is suitable and efficient for
the diagnosis of neuromuscular diseases and the analysis
of large genes such as NEB, frequently mutated in NM
[15]. This approach also covers any newly discovered
gene for the disorder. For all patients presented here we
found known or novel variations in the NEB gene.
These changes were confirmed by Sanger sequencing,
and their familial segregation validated when parent
DNA available. In all the patients, at least one of the
two compound heterozygous mutations was a truncating
mutation (frameshift or nonsense mutation) leading to
protein truncation or degradation, or both (Table 1). The
second mutations were, either a frameshift mutation,
deletion of several amino acids in frame (splice site
mutations), a non-conservative missense change close
to an actin binding site (P13), or synonymous variants
in P3, P8, and P11 that all impacted on splicing. Most
of the mutations (18) affected ubiquitously expressed
exons, while six were in the alternatively spliced exons
and one in an exon of the triplicated region of eight
exons. Overall, most mutations were predicted to lead
to a truncated or absent protein. There was no obvious
correlation between the type of mutation or its location
on the protein and the clinical severity.
Morphological findings
Histological and histochemical features
Group 1
A similar morphological pattern characterised by marked
fibre size variability was noted in all biopsies from G1. We
constantly identified two populations of fibres; the first
characterized by muscle fibres of predictably normal or
slightly augmented size, and the second one consisting of
severely atrophic fibres (Figure 1A; arrows). Small rounded/
globular inclusions staining red by the mGT, corresponding
to nemaline bodies, were present in less than half of
muscle fibres (Figure 1A). Nemaline bodies occupied
both normal-sized and atrophic fibres (Figure 1A). They
presented a dispersed or, more often, a subsarcolemmal
distribution (Figure 1A). Some atrophic fibres appeared
completely occupied by nemaline bodies. The percentage
of muscle fibres harbouring rods was to 22% to 33%
(Figure 1D, Group 1, red). The oxidative enzyme reactions
revealed more than 30% of fibres presenting uneven
staining of the intermyofibrillar network (not shown).
The latter did not always correspond to the areas occupied
by nemaline bodies, suggesting the presence of some
degree of sarcomeric disruption. ATPase techniques did
not reveal type 1 fibre predominance in any of the patientsin G1. The majority of fibres staining differently from type
1 are probably undifferentiated fibres (not shown).
Group 2
The morphological pattern found in this group was
heterogeneous compared with G1 biopsies. While in
P6, and P7 samples we noticed the presence of two
populations of muscle fibres (predictably normal size and
severely atrophic) (Figure 1B; arrows), P8, and P9 showed a
mild variation of fibres size without any particular
topography (not shown). Conversely to G1 nemaline
bodies were present in the vast majority of fibres
(mean: 95% to 100%; Figure 1D, Group 2, blue) and
presented a variable shape varying from oval to elongated.
The oxidative enzyme reactions revealed some alteration
of the intermyofibrillar network, probably corresponding
to rod accumulation or myofibrillar disorganization with
oxidative techniques. ATPase techniques showed type 1
fibre predominance in P6, and P8. Type 1 uniformity was
noted in P7 and P9.
Group 3
In this group we noticed mild variation of fibre size except
in P12 where some atrophic rounded fibres were identified
(not shown). Nemaline bodies presented a constant
elongated shape and formed well separated clusters both
in subsarcolemmal and cytoplasmic areas (Figure 1C).
There was a large variability in the percentage of fibres
harbouring rods. While P10, P13 and P14 presented rods
in almost all fibres (97-99%), P11 had 60% and P12 31% of
fibres with rods, respectively (Figure 1D, Group 3, green).
ATPase techniques showed almost complete type 1
uniformity in G3 muscle biopsies. The areas of muscle
fibres containing rods lacked ATPase staining.
Summary
Overall, severe NM was associated with a fibre size
variability, presence of rods in about 1/3 of fibres,
and a high percentage of undifferentiated fibres. By
contrast a higher percentage of fibres with rods, and
a type 1 fibre predominance/uniformity was noted in the
intermediate and typical NM patients. The amount of
nemaline bodies seems to be inversely related to clinical
severity.
Immunohistochemistry and immunofluorescence
Group 1
In P1 we identified many fibres expressing developmental,
neonatal, fast and/or slow myosin. Immunofluorescence
studies showed absence of type 2X myosin.
Group 2
In P6 we identified many fibres co-expressing slow and
fast myosins. Developmental and neonatal myosins were
Figure 1 Light microscopy and percentage of fibers with rods. Modified Gomori trichrome stainings. A and B. Nemaline bodies in muscle
biopsies from P2 (G1) and P7 (G2) have a rounded/ovoid shape. They are present in both normal size, and atrophic fibres (indicated by arrows).
C. Nemaline bodies in muscle biopsy from P11 have an elongated shape (indicated by arrows) and they are localized in subsarcolemmal and
perinuclear areas. Scale bars represent 20 μm for mGT stainings. D. Representation of percentage of rod occupied fibres in Group 1 (red), Group 2
(blue), and Group 3 (green). See text for explanations.
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http://www.actaneurocomms.org/content/2/1/44expressed in a minority of fibres. In P8 we identified
occasional fibres expressing developmental myosin and
less than 5% of fibres expressing neonatal myosin; there
was partial co-expression of fast and slow myosins. P9
showed unique expression of slow myosin both in im-
munohistochemical, and immunofluorescence studies.Group 3
P10, P11, and P14 showed slow myosin uniformity using
both techniques. No fibres expressing developmental
and/or neonatal myosins were noted.Electron microscopy
Group 1
The prominent ultrastructural finding in all G1 patients
was the diffuse myofibrillar dissociation. The myofibrils
appeared thinner, and smaller than in age-matched
controls (Figure 2A). The latter suggested either a defect
in sarcomeric structure establishment either the lost of it.
Remnants of sarcomeres were intermingled with organ-
elles (e.g. mitochondria) or glycogen granules (Figure 2A).
Globular/ovoid nemaline bodies were scattered or distrib-
uted in subsarcolemmal and perinuclear areas (Figure 2B,
and C). Some fibres were completely occupied by them
(Figure 2C). At higher magnification globular/ovoid rodspresented thin filaments projecting from their thinnest
edges (Figure 2D).Group 2
This group presented a milder degree of myofibrillar
dissociation accompanying dispersed or clustered nemaline
bodies (Figure 3A, and 3B). Rods showed the typical lattice
structure resembling Z-disc material at very high magnifi-
cation (Figure 3C). In P9 we noticed the presence of some
typical cytoplasmic bodies with a dense core, and a clear
halo of fine filaments (not shown).Group 3
We found a homogenous picture characterised by the
presence of well-separated clusters of subsarcolemmal
(Figure 4A), perinuclear, and less often cytoplasmic
nemaline bodies (Figure 4B). The rods were always
surrounded by thin filaments and amorphous mater-
ial. The sarcomeric structure was overall conserved
(Figure 4A, and 4B).Summary
Taken together, our results suggest that myofibrillar
dissociation correlated with clinical severity.
P1 BP2
P3 P4
A
C D
*
Figure 2 Electron microscopy for group G1-severe NM. A. P1. Sarcomeric structure is completely disrupted. Fragment of sarcomeres are
intermingled with amorphous material containing organelles and glycogen granules. B. P2. Scattered globular ovoidal nemaline bodies are found
inside a fiber showing partial sarcomeric alteration. C. P3. Presence of three muscle fibres presenting different degree of alterations. Nemaline
bodies are found in subsarcolemmal areas (indicated by an arrow). The fibre above the first one shows sarcomeric disarray and thicknened Z-lines
probably leading to globular rods formation (indicated by an asterisk). A small atrophic fibre is completely invaded by rounded nemaline bodies
(indicated by a star). D. P4. Globular nemaline bodies present thin filaments coming out from the thinner edges. Original magnification: A. 11,000x.
B. 7,000x C. 8,400x D. 51,000x.
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The maximal force generation capacity of the muscle fibre
preparations was normalized to their cross-sectional area
(i.e. maximal active tension) (Figure 5). An overview of
the maximal active tension and the rate of tension
redevelopment of the muscle fibres are summarized in
Table 2. Data are presented as mean ± SEM.
Myosin heavy chain analyses
The myosin heavy chain (MHC) gel electrophoresis
experiments revealed that muscle preparations from
biopsies from patient P1 contained both neonatal isoforms
as well as type 1 and type 2A isoforms: (9.2 ± 2.8% MHC
neonatal; 40.0 ± 3.2% MHC type 1; 50.8 ± 1.3% MHC type
2A). Muscle preparations from biopsies of P7 and P8
(group 2) contained both MHC type 1 and MHC type 2A
isoforms: P7 (66.6 ± 6.6% MHC type 1 and 33.4 ± 6.6%
MHC type 2A) and P8 (40.8 ± 12.0% MHC type 1 and
59.2 ± 12.0% MHC type 2A), respectively. All other patient
biopsies (P9, P10, P11 and P14) showed exclusively
myosin heavy chain type 1 isoforms.
Discussion
In our tertiary Center for Neuromuscular Disorders we
perform a detailed clinical, morphological, and genetic
analysis of large cohorts of patients presenting NM. Dueto the genetic heterogeneity of NM, and the difficulties
encountered in the molecular screening of the ‘giant’
NEB gene [15,35], in France and Finland an integrated
approach combining next generation sequencing and
dHPLC/Sanger sequencing was set-up. Our strategy
allowed the identification of ten new families harbouring
NEB mutations. All patients presented autosomal reces-
sive pattern of inheritance and either homozygous or
compound heterozygous pathogenic variants. Our results
confirm that NEB is one of the most frequently mutated
NM genes, accounting for almost half of the genetically
identified NM patients screened for the known genes
associated with NM [3-11].
We undertook a detailed clinical histological, and,
when possible, muscle functional analysis in a cohort of
fourteen NEB-mutated subjects whose muscle biopsy was
available in our laboratory. We comment on relevant
findings encountered.
NEB-mutated patients revealed a wide pathological
spectrum and showed recurrent morphological pattern
with some overlap among the clinical groups. Lethal/severe
NM subjects (G1) presented: high degree of myofibrillar
dissociation and smallness revealed by electron microscopy,
scattered globular/ovoid nemaline bodies occupying one
third of muscle fibres, and absence of type 1 predominance
with myosins ATPases techniques (Figure 2). Intermediate
B P9P7
C
A
Figure 3 Electron microscopy for group G2-intermediate NM. A. P7. Globular ovoid nemaline bodies associated with partial sarcomeric
disarray strongly resembling the pathologic picture of G1. B. P9. Presence of elongated nemaline bodies in perinuclear and subsarcolemmal areas.
The latter are well separated from well-preserved sarcomeric structure. C. P9. Higher magnification of an elongated nemaline body. The
typical periodic net structure composing rods is clearly recognisable. Thin filament spread out of the thinnest edges of rods. Sparse thin filaments
are found around the rods intermingled with glycogen granules. Original magnification: A. 11,000x B. 6,400x C. 94,000x.
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to G1 in P6 and P7, even though the presented
higher percentage of rods and type 1 predominance,
and well-separated clusters of rods associated with
type 1 predominance or uniformity in the other patients.
It is noteworthy that P6 and P7 deceased at 5 months,
and 2 and a half year, respectively. For this reason these
patients could be considered as a ‘Longer survivor severe
congenital NM’ subgroup due to their ‘midway’ clinicalA
P10
Figure 4 Electron microscopy for group G3-typical-mild NM. A. P10, G
a cluster of elongated nemaline bodies in the subsarcolemmal areas of mu
thin filaments. Original magnification: A. 9,000x B. 8,200x.and morphological features between G1 and G2. Group 3
had a preserved sarcomeric structure with clusters of
elongated rods invariantly associated with type 1 predom-
inance/uniformity.
In summary we show a large pathological spectrum
ranging from severely damaged sarcomeres with scattered
nemaline bodies to globally preserved muscle with clusters
of well separated rods occupying the majority of myofibres.
Interestingly the degree of sarcomeric disruption directlyB
P14
3. Presence of globally preserved sarcomeric structure associated with
scle fibres. P10. B. P14. Well-delimited clusters of rods surrounded by
Activation
solution 
at 20 C
K
manoeuvre
Relax
solution
Activation
solution 
at 1 C
Figure 5 Typical force traces of skinned myofibers from
nemaline myopathy patients with nebulin mutations. Typical
examples from force traces of a skinned muscle preparation from P1
from Group1 (in grey) and P9 from Group2 (in black). Myofibres are
pre-activated by exposure to an activation solution at 1°C. By rapid
switching to an activation solution at 20°C, the fibers are activated
and force is generated. When the force trace reaches a plateau, the
myofibres are slacked to 70% of their original length followed by a rapid
restretch to the original length after 30 milliseconds (Ktr manouvre).
When force generation has reached a plateau again, the muscle
preparation is exposed to a calcium-free solution to induce relaxation.
Malfatti et al. Acta Neuropathologica Communications 2014, 2:44 Page 12 of 14
http://www.actaneurocomms.org/content/2/1/44related to clinical severity whereas the number of rod
invaded fibres seemed to be inversely correlated.
We undertook this study to search for genotype-
phenotype correlations. Taken together, the vast majority
of NEB mutations are predicted to lead to a degradation
and or denaturation of many nebulin isoforms. Markedly
reduced amounts of nebulin in muscle samples from
patients homozygous for exon 55 deletions have been
reported previously [36]. P2 in this study is homozygous
for the same exon 55 deletion, resulting in an in-frame
deletion of 35 amino acids, and subsequent protein
degradation. Nonsense mRNA-mediated decay was
demonstrated by RT-PCR in P1, who carries a heterozygous
nonsense mutation in exon 45. P1 is also heterozygous for
a splice site mutation in intron 122, which was shown to
cause exon 122 skipping, resulting in in-frame deletion of
35 amino acids [15]. Splice site mutations are, however,
often “leaky”, i.e. some transcripts are spliced correctly,
whereas others are incorrectly spliced. Therefore, it seems
plausible that P1, as well as the other patients with splice
site mutations (P3, P6, P8, P10, P11, P12 and P14) express
small amounts of normal nebulin in their muscles.
Markedly reduced amounts of nebulin in muscle have
been reported in one patient compound heterozygous
for a splice site mutation and a frameshift mutation inTable 2 Muscle contractility data of permeabilized fibers from
P1 P7
Maximal active tension (mN/mm2) 8.1 ± 1.5 18.8 ± 2.7
Rate of tension redevelopment (k1 (s
−1)) 5.1 ± 0.4 4.5 ± 0.7constitutively expressed exons [37]. The mutations in
alternatively spliced exons (exons 174, 175, 176 and 177)
only affect nebulin isoforms expressing these exons,
leaving other isoforms unaffected. Consequently reduced
amounts of nebulin and absence of some isoforms, preclud-
ing an appropriate thin filaments assembly, might be re-
sponsible for the drastic myofibrillar dissociation revealed
in G1 [Figure 4]. Functional studies confirmed that G1
patients’ muscle fibers generate very low force. Although
one could argue that age confounded our findings, previous
work from our group revealed no major differences in the
contractile performance of myofibres isolated from young
(age 2–5 years) versus adult (age 20–30) human control
biopsies [37]. Note that G1 patients’ muscle fibres
expressed only very low levels of neonatal myosin heavy
chain isoforms; such low levels are unlikely to account for
the major loss of force in this patient. We therefore suggest
that nebulin degradation/absence translates into sarcomeric
disarray and/or altered actomyosin interaction. This
could be responsible for low force generation producing
global hypotonia, muscle akinesia, and arthrogryposis.
Concordantly, a recent study reported that low levels
of nebulin in skeletal muscle are probably responsible
for the foetal akinesia and arthrogryposis sequence
phenotype [36].
How nebulin deficiency results in nemaline bodies
formation is yet to be understood. Some authors suggested
that a truncated nebulin would disrupt myofibrillar con-
nectivity leading to Z-disc displacement and, eventually,
rods formation [38]. Analysis of nemaline bodies features in
our cohort revealed differences in shape across the three
groups. These tended to be globular/ovoid in G1, elongated
in the other groups. The specificity of this finding is
uncertain. What is more striking is that in P8, and P9 from
G2 and in all G3 patients, the majority of fibres harboured
rod clusters confined to subsarcolemmal and/or perinuclear
areas. The myofibrillar structure surrounding them was
overall preserved. Some unknown process could try to
circumscribe the protein aggregates and avoid a perturb-
ation of muscle contraction. This could explain why muscle
fibers in G2 and G3 patients showed a better contractile
performance, probably translating into a milder clinical
phenotype. It is tempting to speculate that mutations
encountered in these groups affect only specific nebulin
isoforms, which is certainly true for patients P7, P8, P9,
P11, and P14 who all have at least one mutation in
an alternatively spliced exon. In this scenario, residual
normal isoforms could allow a proper thin filamentnemaline myopathy patients with NEB mutations
P8 P9 P10 P11 P14
76.9 ± 10.0 90.9 ± 10.5 55.5 ± 7.1 102.2 ± 21.2 61.4 ± 12.2
5.0 ± 0.5 3.4 ± 0.2 3.6 ± 0.2 4.0 ± 0.6 3.8 ± 0.5
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for protein aggregation/rod formation. If this turned
to be true, the presence of rods might be considered
unrelated to muscle contractility disturbances. Following
this reasoning we could imagine that an additive effect
of degraded nebulin isoforms would determine clinical
severity.
Type 1 predominance or type uniformity has been
reported as a very common feature associated with NM,
and many other structural congenital myopathies [39]. It
is speculated that this is due to a disturbance of fibre
differentiation before phase three of muscle differentiation
(35th weeks) [40]. A severe NEB mutated family composed
by two brothers has been reported as not having type 1
fibre predominance. However, biopsied muscle and age at
muscle biopsy were not specified [41]. In the present study
we performed type fibre distribution analysis on ATPase
techniques. Surprisingly, all G1 patients failed to show type
1 predominance and constantly showed absence of 2B
fibers. Immunostainings for different myosins isoforms
(foetal neonatal, fast and slow) revealed a certain
degree of myosin isoforms co-expression in numerous
fibres suggesting the presence of undifferentiated fibers.
This contrasted with the other groups where type 1 pre-
dominance/uniformity was present. This finding suggests
that G1 NEB-mutated patients were not able to switch
towards type 1 predominance due to a possible alteration
of muscle maturation. It is tempting to speculate that
aberrations in fibre-typing, and absence of type 2B seen
with ATPase techniques are due to changes in isoforms
imbalance more than related to age at muscle biopsy.
Additionally the presence of high percentages of undiffer-
entiated fibres encountered in G1 might turn out to be an
important prognostic factor. In fact muscle biopsy analysis
of new-borns presenting arthrogryposis and a pathological
picture characterised by sarcomeric dissociation, scattered
nemaline bodies absence of type 1 predominance and type
2B fibres with ATPases techniques might orientate toward
NEB mutations. This is something distinctive from other
severe form of congenital myopathies commonly showing
type 1 predominance as a prominent feature [42]. In
particular we recently demonstrated that MTM1-mutated
boys presenting an extremely severe clinical phenotype all
had type 1 predominance in their biopsies, regardless of
the biopsied muscle, and the gestational age [28].
In conclusion, this study adds on the clinical, morpho-
logical and functional characterization of the most recurrent
form of NM. We assessed morphological and functional
heterogeneity in NEB-mutated NM patients and identified
a correlation between disease severity on the one hand, and
ultrastructural myofibrillar abnormalities and contractility
on the other. We suggest that myofibrillar dissociation and
smallness is a primary defect causing the disease while
nemaline bodies could be due to a collateral mechanism.Competing interests
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